Jeffrey Girshman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey Girshman has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Plodkowski
Memorial Sloan Kettering Cancer Center, New York, USA
42 shared publications - Kathryn Cecilia Arbour
Memorial Sloan Kettering Cancer Center 8 Thoracic Oncology Service, Department of Medicine New York, New York
41 shared publications - Matthew D. Hellmann
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
41 shared publications - Peter Sawan
Memorial Sloan Kettering Cancer Center, New York, United States
37 shared publications - Celeste Yu
Princess Margaret Cancer Centre 4 Toronto, ON
36 shared publications - Christine Micheel
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
36 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 3: PFS estimates for patients with NSCLC treated with standard first- and second-line therapies.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 1 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 1 from The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Supplemental Figure 1: OS and PFS for KRAS-mutated NSCLC treated with first-line platinum-based chemotherapy.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from The GENIE BPC NSCLC cohort: a real-world repository integrating standardized clinical and genomic data for 1,846 patients with non-small cell lung cancer
Supplemental Figure 2: OS and PFS for patients with NSCLC treated with first-line platinum-based chemotherapy.